
Christoph Heuck MD
Myeloproliferative Disorder Hematology-Oncology
Physician
Join to view full profile
111 E 210th StHoffheimer Building 2nd Fl.Bronx, NY 10467
Phone+1 718-920-4826
Dr. Heuck is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Montefiore Medical Center/Albert Einstein College of Medicine (Moses and Weiler Campuses)Fellowship, Hematology and Medical Oncology, 2007 - 2010
Montefiore Medical Center/Albert Einstein College of Medicine (Moses and Weiler Campuses)Residency, Internal Medicine, 2004 - 2007
Humboldt University of Berlin - Charite Faculty of MedicineClass of 2003
Certifications & Licensure
AR State Medical License 2011 - 2016
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory 2014 Certified EHR Suite, Epic Systems Corporation, 2016
Clinical Trials
Publications & Presentations
PubMed
- 34 citationsClinical Management of Patients With Relapsed/Refractory Multiple Myeloma Treated With Talquetamab.Ajai Chari, Amrita Krishnan, Leo Rasche, Jing Christine Ye, Alfred Garfall
Clinical Lymphoma, Myeloma & Leukemia. 2024-10-01 - 87 citationsEVIDENCE meta-analysis: evaluating minimal residual disease as an intermediate clinical end point for multiple myeloma.Ola Landgren, Thomas J Prior, Tara Masterson, Christoph Heuck, Orlando F Bueno
Blood. 2024-07-25 - 4 citationsCorrection: GPRC5D as a novel target for the treatment of multiple myeloma: a narrative review.Paula Rodriguez-Otero, Niels W C J van de Donk, Kodandaram Pillarisetti, Ingrid Cornax, Deeksha Vishwamitra
Blood Cancer Journal. 2024-03-06
Press Mentions
New Analyses Demonstrate Versatility and Continued Efficacy of TALVEYtm in the Treatment of Patients with Relapsed or Refractory Multiple MyelomaDecember 16th, 2023
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:









